公开(公告)号：US20130338544A1

公开(公告)日：2013-12-19

申请号：US13902644

申请日：2013-05-24

Applicant: David W. Newell

Inventor： David W. Newell

IPC: A61N7/02

CPC classification number: A61N7/02 ,  A61B8/06 ,  A61B8/0808 ,  A61B8/488 ,  A61B17/22004 ,  A61B90/10 ,  A61N7/00 ,  A61N2007/0021 ,  A61N2007/0052 ,  A61N2007/0078

Abstract: Methods for treating a human patient having a subarachnoid hematoma, such as to prevent cerebral vasospasm or to reduce the severity of cerebral vasospasm in the patient, and associated devices, systems, and methods are disclosed herein. In a particular embodiment, a thrombolytic agent is introduced extravascularly into a subarachnoid region including the hematoma. A headset configured for hands-free delivery of transcranial ultrasound energy is connected to the patient and used to deliver ultrasound energy to the subarachnoid region to enhance the thrombolytic effect of the thrombolytic agent. The type and/or dosage of the thrombolytic agent can be selected based on the enhanced thrombolytic effect. For example, the enhanced thrombolytic effect can allow the therapeutically effective use of less aggressive thrombolytic agents and/or lower dosages of thrombolytic agents. In some cases, this can reduce the clinical probability of additional cerebral hemorrhage.

Abstract translation: 本文公开了用于治疗具有蛛网膜下血肿的人患者的方法，例如用于预防脑血管痉挛或降低患者脑血管痉挛的严重性，以及相关的装置，系统和方法。 在一个具体的实施方案中，血栓溶解剂引入包括血肿的蛛网膜下区域。 被配置为用于免提递送经颅超声能量的耳机连接到患者，并用于将超声能量输送到蛛网膜下区域以增强溶栓剂的溶栓作用。 溶血栓剂的类型和/或剂量可以基于增强的血栓溶解作用来选择。 例如，增强的血栓溶解作用可以允许治疗有效地使用较少侵袭性溶栓剂和/或较低剂量的溶栓剂。 在某些情况下，这可以降低额外的脑出血的临床概率。

公开(公告)号：US20180154187A1

公开(公告)日：2018-06-07

申请号：US15803702

申请日：2017-11-03

Applicant: David W. Newell

Inventor： David W. Newell

IPC: A61N7/02 ,  A61B17/22 ,  A61B90/10 ,  A61N7/00 ,  A61B8/08 ,  A61B8/06

CPC classification number: A61N7/02 ,  A61B8/06 ,  A61B8/0808 ,  A61B8/488 ,  A61B17/22004 ,  A61B90/10 ,  A61N7/00 ,  A61N2007/0021 ,  A61N2007/0052 ,  A61N2007/0078

Abstract: Methods for treating a human patient having a subarachnoid hematoma, such as to prevent cerebral vasospasm or to reduce the severity of cerebral vasospasm in the patient, and associated devices, systems, and methods are disclosed herein. In a particular embodiment, a thrombolytic agent is introduced extravascularly into a subarachnoid region including the hematoma. A headset configured for hands-free delivery of transcranial ultrasound energy is connected to the patient and used to deliver ultrasound energy to the subarachnoid region to enhance the thrombolytic effect of the thrombolytic agent. The type and/or dosage of the thrombolytic agent can be selected based on the enhanced thrombolytic effect. For example, the enhanced thrombolytic effect can allow the therapeutically effective use of less aggressive thrombolytic agents and/or lower dosages of thrombolytic agents. In some cases, this can reduce the clinical probability of additional cerebral hemorrhage.

公开(公告)号：US09808653B2

公开(公告)日：2017-11-07

申请号：US13902644

申请日：2013-05-24

Applicant: David W. Newell

Inventor： David W. Newell

IPC: A61H1/00 ,  A61N7/02 ,  A61N7/00 ,  A61B17/22 ,  A61B90/10 ,  A61B8/08 ,  A61B8/06

CPC classification number: A61N7/02 ,  A61B8/06 ,  A61B8/0808 ,  A61B8/488 ,  A61B17/22004 ,  A61B90/10 ,  A61N7/00 ,  A61N2007/0021 ,  A61N2007/0052 ,  A61N2007/0078

Abstract: Methods for treating a human patient having a subarachnoid hematoma, such as to prevent cerebral vasospasm or to reduce the severity of cerebral vasospasm in the patient, and associated devices, systems, and methods are disclosed herein. In a particular embodiment, a thrombolytic agent is introduced extravascularly into a subarachnoid region including the hematoma. A headset configured for hands-free delivery of transcranial ultrasound energy is connected to the patient and used to deliver ultrasound energy to the subarachnoid region to enhance the thrombolytic effect of the thrombolytic agent. The type and/or dosage of the thrombolytic agent can be selected based on the enhanced thrombolytic effect. For example, the enhanced thrombolytic effect can allow the therapeutically effective use of less aggressive thrombolytic agents and/or lower dosages of thrombolytic agents. In some cases, this can reduce the clinical probability of additional cerebral hemorrhage.